Nutriband Inc.

NTRB Healthcare Biotechnology

Nutriband Inc.’s revenue for fiscal 2026 (year ended January 2026) was $2.0 million, down 4.80% from fiscal 2025. In the quarter to July 2026, revenue fell 29.7%, EPS grew 96.7%, free cash flow grew 55.5% and total debt fell 46.9%, each against the same quarter a year earlier.

6.22 0.05 −0.80%
Market cap
$76.2M
P/E
0.0×
Fwd P/E
4.6×
Dividend yield
—
F-score
3/9
Altman Z
27.17
Beneish M
−3.51
Dividend safety
n/a
Older periods Oct '25 Jan '26 Apr '26 Jul '26
Piotroski F-Score

+8 more TTM periods

5 3 4 3
ROE
(368.44%) (458.50%) (539.15%) (100.79%)
ROA
(330.04%) (400.11%) (458.38%) (84.56%)
ROIC
(352.65%) (242.87%) (253.24%) (227.92%)
Return on Tangible Assets
(614.36%) (629.63%) (730.55%) (202.27%)
Average Days of Receivables
23.65 21.22 0.53 5.32
Free Cash Flow per Share
(0.47) (0.44) (0.36) (0.30)
Free Cash Flow
(5.65) (5.14) (4.36) (3.63)
Other line items

Show all line items

Columns are period end dates